p53 Immunohistochemistry for distinguishing reactive mesothelium from low grade ovarian carcinoma

Acta Cytologica

Volumn 44, Issue 1, 2000, Pages 31-36

  Pindzola, J Ander ^a   Kovatich, Albert J ^a   Bibbo, Marluce ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Immunohistochemistry; Ovarian neoplasms; p53 protein

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CLINICAL ARTICLE; FEMALE; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESOTHELIUM; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0033978126     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000326221     Document Type: Article

References (14)

1. Sherman ME: Cytopathology. In Blaustein's Pathology of the Female Gential Tract. Fourth edition. Edited by RJ Kurman. New York, Springer-Verlag, 1994, pp 1123-1125
2. Rosai J: Female reproductive system. In Ackerman's Surgical Pathology. Eighth edition. Edited by J Rosai. Philadelphia, CV Mosby, 1996, pp 1461-1539
3. Bischof P: What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol 1993;49:93-98
4. Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger L, Stadlmann S, Daxenbichler G, Dapunt O: Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol 1996;62:384-389
5. Hollstein M, Sidransky D, Vogelstein B: p53 Mutations in human cancers. Science 1991:253;49-53
6. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, Parkin DE, Haites NE: p53 Mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993;53:2128-2132
7. Baas IO, Mulder JR, Offerhaus GJA, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12
8. Klemi PJ, Takahashi S, Joensuu H, Külholma P, Narimatsu E, Mori M: Immunohistochemical detection of p53 in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994;13:228-233
9. Sherr CJ: Cancer cell cycles. Science 1996;274:1672-1677
10. Mullick SS, Green LK, Ramzy I, Brown RW, Smith D, Gondo MM, Cagle PT: p53 Gene product in pleural effusions: Practical use in distinguishing benign from malignant cells. Acta Cytol 1996;40:855-860
11. van Haaften-Day C, Russel P, Boyer CM, Kerns BM, Wiener JR, Jensen DN, Bast RC, Hacker NF: Expression of cell regulatory proteins in ovarian borderline tumors. Cancer 1996;77:2092-2098
12. Lee JL, Kang YS, Park SY, Kim BG, Lee ED, Lee KH, Park KB, Kavanagh JJ, Wharton JT: p53 Mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 1995;85:43-50
13. Teh M, Lee YS: An immunohistochemical study of p53 protein in ovarian mucinous neoplasms. Pathology 1996;28:217-219
14. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR: p53 And HER-2/neu overexpression in ovarian borderline tumors. Gynecol Oncol 1997;65:218-224